• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鼻咽癌细胞系中C-KIT的过表达与突变以及伊马替尼对这些细胞系的反应性。

C-KIT overexpression and mutation in nasopharyngeal carcinoma cell lines and reactivity of Imatinib on these cell lines.

作者信息

Huang Pei-Yu, Hong Ming-Huang, Zhang Xing, Mai Hai-Qiang, Luo Dong-Hua, Zhang Li

机构信息

State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, PR China.

出版信息

Chin J Cancer. 2010 Feb;29(2):131-5. doi: 10.5732/cjc.009.10411.

DOI:10.5732/cjc.009.10411
PMID:20109338
Abstract

BACKGROUND AND OBJECTIVE

We previously reported that C-KIT overexpression and mutation exist in biopsy samples of nasopharyngeal carcinoma (NPC). Yet whether Imatinib had an inhibitory effect on the proliferation of NPC in vitro was still unknown. So, this study examined whether sensitivities to Imatinib of other cell lines are different and whether C-KIT expression and mutations exist, to analyze the correlations between them.

METHODS

The expression of C-KIT in NPC cell lines, including CNE-1, CNE-2, Hone-1, C-666, SUNE-1, 5-8F, and nasopharyngeal epithelial (NPE) cell line NP-69, were detected by Western blot. Direct sequencing of polymerase chain reaction (PCR) products was performed to analyze the sequences of C-KIT from the above-mentioned cell lines. Inhibitory effects on proliferation by Imatinib on these cell lines were determined by CCK-8 assay. Pearson product moment correlation and t test were used to analyze the correlation betweeen C-KIT overexpression, C-KIT gene mutation, and the inhibitory effect of Imatinib.

RESULTS

Compared with NPE cell line NP-69, NPC cell lines CNE-1, CNE-2, Hone-1, C-666, SUNE-1, and 5-8F had significantly higher levels of C-KIT expression. Heterozygous IVS17+78T>C were found in CNE-1, CNE-2, Hone-1, and NP-69 cell lines, homozygous IVS17+78T>C was found in C-666, and no mutation was found in SUNE-1 or 5-8F. Imatinib had a dose-dependent inhibitory effect on proliferation for CNE-1, CNE-2, Hone-1, C-666, SUNE-1, and 5-8F. No significant correlation between the inhibitory effects of Imatinib, C-KIT overexpression, or C-KIT mutation was found.

CONCLUSION

C-KIT overexpression and intron mutation were found in NPC cell lines and Imatinib had a dose-dependent inhibitory effect on proliferation for NPC cell lines, yet no significant correlation between C-KIT overexpression, C-KIT mutation, or the inhibitory effect of Imatinib was found.

摘要

背景与目的

我们之前报道过,在鼻咽癌(NPC)活检样本中存在C-KIT过表达和突变。然而,伊马替尼在体外对NPC增殖是否具有抑制作用仍不清楚。因此,本研究检测了其他细胞系对伊马替尼的敏感性是否不同以及是否存在C-KIT表达和突变,以分析它们之间的相关性。

方法

通过蛋白质免疫印迹法检测NPC细胞系(包括CNE-1、CNE-2、Hone-1、C-666、SUNE-1、5-8F)及鼻咽上皮(NPE)细胞系NP-69中C-KIT的表达。对上述细胞系的C-KIT进行聚合酶链反应(PCR)产物直接测序以分析其序列。采用CCK-8法检测伊马替尼对这些细胞系增殖的抑制作用。使用Pearson积矩相关分析和t检验分析C-KIT过表达、C-KIT基因突变与伊马替尼抑制作用之间的相关性。

结果

与NPE细胞系NP-69相比,NPC细胞系CNE-1、CNE-2、Hone-1、C-666、SUNE-1和5-8F的C-KIT表达水平显著更高。在CNE-1、CNE-2、Hone-1和NP-69细胞系中发现杂合子IVS17+78T>C,在C-666中发现纯合子IVS17+78T>C,而在SUNE-1或5-8F中未发现突变。伊马替尼对CNE-1、CNE-2、Hone-1、C-666、SUNE-1和5-8F的增殖具有剂量依赖性抑制作用。未发现伊马替尼的抑制作用、C-KIT过表达或C-KIT突变之间存在显著相关性。

结论

在NPC细胞系中发现C-KIT过表达和内含子突变,且伊马替尼对NPC细胞系的增殖具有剂量依赖性抑制作用,但未发现C-KIT过表达、C-KIT突变与伊马替尼抑制作用之间存在显著相关性。

相似文献

1
C-KIT overexpression and mutation in nasopharyngeal carcinoma cell lines and reactivity of Imatinib on these cell lines.鼻咽癌细胞系中C-KIT的过表达与突变以及伊马替尼对这些细胞系的反应性。
Chin J Cancer. 2010 Feb;29(2):131-5. doi: 10.5732/cjc.009.10411.
2
Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.伊马替尼对胃肠道间质瘤细胞系的作用因KIT突变类型而异。
Oncol Rep. 2005 Sep;14(3):645-50.
3
Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo.口服变构AKT抑制剂(MK-2206)对人鼻咽癌的体内外作用
Drug Des Devel Ther. 2014 Oct 10;8:1827-37. doi: 10.2147/DDDT.S67961. eCollection 2014.
4
Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.激酶抑制剂SU11248对甲磺酸伊马替尼耐药的胃肠道间质瘤突变体的疗效。
Clin Cancer Res. 2006 Apr 15;12(8):2622-7. doi: 10.1158/1078-0432.CCR-05-2275.
5
Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.伊马替尼抑制由干细胞因子/KIT受体途径介导的尤因肿瘤细胞增殖,并使细胞对长春新碱和阿霉素诱导的凋亡敏感。
Clin Cancer Res. 2004 Jan 15;10(2):751-61. doi: 10.1158/1078-0432.ccr-0778-03.
6
Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors.伊马替尼可抑制胃肠道间质瘤中发现的各种类型的活化突变型KIT。
Int J Cancer. 2003 May 20;105(1):130-5. doi: 10.1002/ijc.11025.
7
Nasopharyngeal carcinoma with non-squamous phenotype may be a variant of nasopharyngeal squamous cell carcinoma after inhibition of EGFR/PI3K/AKT/mTOR pathway.非鳞状表型的鼻咽癌可能是 EGFR/PI3K/AKT/mTOR 通路抑制后的鼻咽鳞状细胞癌的一种变异型。
Histol Histopathol. 2024 May;39(5):647-657. doi: 10.14670/HH-18-673. Epub 2023 Nov 8.
8
Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.甲磺酸伊马替尼在体内抑制恶性纤维组织细胞瘤细胞的致瘤性。
Anticancer Res. 2007 Jan-Feb;27(1A):423-9.
9
Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?甲磺酸伊马替尼(STI571;格列卫)——治疗胆管癌的新方法?
Anticancer Drugs. 2003 Oct;14(9):751-60. doi: 10.1097/00001813-200310000-00011.
10
[Effect of tyrosine kinase inhibitor Imatinib mesylate on proliferation, differentiation and apoptosis of Kasumi-1 leukemia cell line].酪氨酸激酶抑制剂甲磺酸伊马替尼对Kasumi-1白血病细胞系增殖、分化及凋亡的影响
Zhonghua Xue Ye Xue Za Zhi. 2005 Aug;26(8):449-52.

引用本文的文献

1
Nasopharyngeal Carcinoma Progression: Accumulating Genomic Instability and Persistent Epstein-Barr Virus Infection.鼻咽癌进展:累积的基因组不稳定性和持续的 Epstein-Barr 病毒感染。
Curr Oncol. 2022 Aug 23;29(9):6035-6052. doi: 10.3390/curroncol29090475.
2
Lapatinib sensitivity in nasopharyngeal carcinoma is modulated by SIRT2-mediated FOXO3 deacetylation.SIRT2 介导的 FOXO3 去乙酰化调控鼻咽癌细胞对拉帕替尼的敏感性。
BMC Cancer. 2019 Nov 14;19(1):1106. doi: 10.1186/s12885-019-6308-7.
3
Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study.
法米替尼联合同期放化疗治疗局部晚期鼻咽癌的 1 期、开放标签、剂量递增研究。
Cancer Commun (Lond). 2018 Nov 1;38(1):66. doi: 10.1186/s40880-018-0330-z.
4
Changes in c-Kit expression levels during the course of radiation therapy for nasopharyngeal carcinoma.鼻咽癌放射治疗过程中c-Kit表达水平的变化。
Biomed Rep. 2016 Oct;5(4):437-442. doi: 10.3892/br.2016.757. Epub 2016 Sep 12.
5
Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma.鼻咽癌中与靶向治疗相关的多种致癌突变。
Chin J Cancer. 2015 Apr 8;34(4):177-83. doi: 10.1186/s40880-015-0011-0.
6
Oncogene mutational profile in nasopharyngeal carcinoma.鼻咽癌中的癌基因突变特征。
Onco Targets Ther. 2014 Mar 20;7:457-67. doi: 10.2147/OTT.S58791. eCollection 2014.
7
Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.双重磷酸肌醇 3-激酶/雷帕霉素哺乳动物靶蛋白抑制剂 NVP-BEZ235 具有治疗潜力,并增敏鼻咽癌中的顺铂。
PLoS One. 2013;8(3):e59879. doi: 10.1371/journal.pone.0059879. Epub 2013 Mar 22.